onr:"swepub:oai:DiVA.org:liu-149494"
Search: onr:"swepub:oai:DiVA.org:liu-149494" > Smoking reduces the...
- 1 of 1
- Previous record
- Next record
- To hitlist
Smoking reduces the efficacy of belimumab in mucocutaneous lupus.
-
- Parodis, Ioannis (author)
- Karolinska Institutet,Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Stockholm, Sweden
-
- Gomez, Alvaro (author)
- Karolinska Institutet,Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Stockholm, Sweden
-
- Frodlund, Martina (author)
- Linköping University,Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Reumatologiska kliniken i Östergötland
- show more...
- show less...
- (creator_code:org_t)
- 2018-07-09
- 2018
- English.
- In: Expert Opinion on Biological Therapy. - : Informa Healthcare. - 1471-2598 .- 1744-7682. ; 18:8, s. 911-920
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- OBJECTIVES: Recently, we demonstrated a negative impact of smoking on belimumab efficacy in patients with systemic lupus erythematosus (SLE). Here, we particularly investigated clinical effects of belimumab and a potential impact of smoking in mucocutaneous and articular SLE.METHODS: We surveyed 62 SLE patients treated between 2011 and 2017. Evaluation included the mucocutaneous descriptors of SLEDAI-2K (rash, alopecia, mucosal ulcers; mcSLEDAI-2K), CLASI, the arthritis SLEDAI-2K descriptor (arSLEDAI-2K) and the 28-joint count.RESULTS: mcSLEDAI-2K and CLASI activity decreased from baseline to month 6 and 12 (P<0.001 for all). No worsening in CLASI damage was observed. Current or previous smokers displayed a higher probability of unchanged/worsened mcSLEDAI-2K compared to never smokers (OR: 6.4; 95% CI: 1.5-27.4; P=0.012), also after adjustment for antimalarial agents. arSLEDAI-2K scores had decreased at month 6 (P<0.001) and 12 (P<0.001). Likewise, tender and swollen 28-joint counts had improved at month 6 (P=0.010 and P<0.001, respectively) and 12 (P=0.001 for both). We observed no impact of smoking on belimumab efficacy in articular SLE.CONCLUSION: We observed a negative impact of smoking on the efficacy of belimumab in mucocutaneous SLE. In contrast, no impact of smoking on belimumab efficacy was seen in patients with articular manifestations.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Keyword
- belimumab
- biological agents
- drug efficacy
- rheumatology
- systemic lupus erythematosus
- Belimumab
- biological agents
- drug efficacy
- rheumatology
- systemic lupus erythematosus
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Expert Opinion on Biological Therapy (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Parodis, Ioannis
- Gomez, Alvaro
- Frodlund, Martin ...
- Jönsen, Andreas
- Zickert, Agneta
- Sjöwall, Christo ...
- show more...
- Bengtsson, Ander ...
- Gunnarsson, Iva
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Rheumatology and ...
- Articles in the publication
- Expert Opinion o ...
- By the university
- Linköping University
- Karolinska Institutet
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
